# Boehringer Ingelheim (Japan)

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/boehringer-ingelheim-japan/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 2 |
| Citations | 87,040 |
| City | Tokyo |
| Country | JP |
| Description | Boehringer Ingelheim (Japan) is a research organisation in Tokyo, JP. OpenAlex records 1,025 works and 87,040 citations for it. 296 researchers list it as their most recent affiliation. |
| Homepage | http://www.boehringer-ingelheim.jp/ |
| OpenAlex ID | https://openalex.org/I4210122708 |
| Region | Tokyo |
| Researchers | 296 |
| ROR ID | https://ror.org/02r1d7x68 |
| Type | company |
| Works | 1,025 |

## University papers

- [The Bidirectional Association of Chronic Kidney Disease, Type 2 Diabetes, Atherosclerotic Cardiovascular Disease, and Heart Failure: The Cardio–Renal–Metabolic Syndrome](https://scholariq.org/papers/the-bidirectional-association-of-chronic-kidney-disease-type-2-diabetes/)
- [Health Care Costs Associated with the Development and Combination of Cardio-Renal-Metabolic Diseases](https://scholariq.org/papers/health-care-costs-associated-with-the-development-and-combination-of-cardio/)
- [HSD80 Evaluation of Methotrexate Based Combinations in Rheumatoid Arthritis Patients: Results from a U.S. Administrative Claims Database](https://scholariq.org/papers/hsd80-evaluation-of-methotrexate-based-combinations-in-rheumatoid-arthritis/)
- [HSD133 Factors Influencing Selection of First Add-on Disease-Modifying Therapy for Rheumatoid Arthritis after Starting Methotrexate](https://scholariq.org/papers/hsd133-factors-influencing-selection-of-first-add-on-disease-modifying-therapy/)
- [The Effect of Cardiometabolic Comorbidities on Risk of Chronic Kidney Disease Incidence: A Longitudinal Cohort Study](https://scholariq.org/papers/the-effect-of-cardiometabolic-comorbidities-on-risk-of-chronic-kidney-disease/)
- [The Effect of Cardiometabolic Comorbidities on Risk of CKD Incidence: A Longitudinal Cohort Study](https://scholariq.org/papers/the-effect-of-cardiometabolic-comorbidities-on-risk-of-ckd-incidence-a/)
- [Budget Impact Analysis for Empagliflozin in Patients with Nondiabetic CKD](https://scholariq.org/papers/budget-impact-analysis-for-empagliflozin-in-patients-with-nondiabetic-ckd/)
- [Uptake of Urine Albumin-to-Creatinine Screening Among US Adults at Risk for CKD: Comprehensive Review of Recent Literature](https://scholariq.org/papers/uptake-of-urine-albumin-to-creatinine-screening-among-us-adults-at-risk-for-ckd/)
- [Quantifying Time to Diagnosis of CKD in the United States](https://scholariq.org/papers/quantifying-time-to-diagnosis-of-ckd-in-the-united-states/)
- [Association between access to care and direct healthcare costs in people with and at high-risk of chronic kidney disease in the United States: a pooled cross-sectional study using the Medical Expenditure Panel Survey](https://scholariq.org/papers/association-between-access-to-care-and-direct-healthcare-costs-in-people-with/)

## University researchers

- [Satabdi Chatterjee](https://scholariq.org/researchers/satabdi-chatterjee/)

## University top topics

Showing 8 of 25.

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Drug Transport and Resistance Mechanisms](https://scholariq.org/topics/drug-transport-and-resistance-mechanisms/)
- [Pharmacogenetics and Drug Metabolism](https://scholariq.org/topics/pharmacogenetics-and-drug-metabolism/)
- [Chemical Synthesis and Analysis](https://scholariq.org/topics/chemical-synthesis-and-analysis/)
- [Drug Solubulity and Delivery Systems](https://scholariq.org/topics/drug-solubulity-and-delivery-systems/)
- [Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis](https://scholariq.org/topics/interstitial-lung-diseases-and-idiopathic-pulmonary-fibrosis/)
- [Analytical Chemistry and Chromatography](https://scholariq.org/topics/analytical-chemistry-and-chromatography/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.